Hong Kong pharmaceutical stocks fell on Wednesday after US President Donald Trump said his administration would soon implement "a major tariff on pharmaceuticals" from foreign nations.
Trump made the remarks at a Republican event, suggesting the move will force drug companies to relocate their operations to the US, according to a USA Today report.
While initially sparing pharmaceuticals from recent tariffs, Trump has indicated for months that the imported drug industry is a future target, the report said.
The news sent shares of Hong Kong-listed drugmakers falling on Wednesday afternoon.
Alphamab Oncology (HKG:9966) led the decliners with an almost 6% fall, followed by Boan Biotech (HKG:6955) with a 5% drop. Luye Pharma (HKG:2186) slid 4.4%, while BeiGene (HKG:6160) and Genscript Bio (HKG:1548) retreated nearly 4%. Zai Lab (HKG:9688) slipped 3%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。